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Methods  33 
Allergen preparations 34 
BL21 Star (DE3) Escherichia coli (Invitrogen, Carlsbad, CA) were transformed with the 35 
p80QE plasmid containing the gene for Fel d 7 (1). Cells were grown for four hours at 37°C 36 
and protein expression was induced by addition of isopropyl-b-thiogalactopyranoside (IPTG) 37 
to a final concentration of 0.5 M for three hours and the cells were subsequently pelleted 38 
(16 800 g, 10min). After sonication (Soniprep 150 ultrasonic disintegrator, Sanyo 39 
Gallenkamp, Uxbridge, UK) by 10 sec (10ma) bursts and centrifugation (16 800 g, 10 min), 40 
the soluble supernatant fraction was sterile filtered and purified twice on 6-His-tag affinity 41 
IMAC Ni
2+
 column (GE healthcare, Uppsala, Sweden) using an ÄKTA purifier (GE 42 
Healthcare) followed by Amicon Ultra 15 (Merck Millipore, Darmstadt, Germany) filtration 43 
in the range from 3 to 30 kDa range. 44 
Recombinant (r) Can f 1 protein was prepared as previously described (2). Briefly, 6-His-45 
tagged Can f 1 was produced by BL21 (DE3) pLysS (Novagen, EMD Chemicals, Darmstadt, 46 
Germany) E.coli transformed with pET20b (Novagen) containing the gene for Can f 1. 47 
Protein concentrations were determined by BCA protein assay (Pierce, Rockford, IL). 48 
Circular dichroism spectroscopy 49 
Circular dichroism (CD)-spectra were recorded on a JASCO J-815 spectropolarimeter 50 
(JASCO, Tokyo, Japan). Samples (0.5 mg/ml of rFel d 7 and rCan f 1 in PBS, pH 7.4) were 51 
analyzed at 25°C in a 0.1 mm path length quartz cell for far-UV and a 10 mm path length 52 
quartz cell for near-UV spectra. The spectra were collected in 0.1 nm steps at a rate of 50 53 
nm/min over the wavelength range 195-260 nm for far-UV and 260–320 nm for near-UV. 54 
Each spectrum was acquired five times and the results were averaged. Results were recorded 55 
in mdeg and converted to molar Δε in M−1 cm−1 and mean residue ΔεMRV for near UV and 56 
far UV, respectively. The percentage of secondary structure motifs were determined in the 57 
CONTIN software with the SP37 protein set in CDPro. 58 
IgE ELISA for Fel d 7 and Can f 1 59 
IgE levels to rFel d 7 and rCan f 1 were determined by enzyme-linked immunosorbent assay 60 
(ELISA) (2, 3).Half-area microtiter plates (96 wells, Greiner bio-one, Frickenhausen, 61 
Germany) were coated overnight at 4°C with 0.5 µg of rFel d 7 or rCan f 1, followed by 62 
blocking (PBS containing 1% BSA and 0.5% Tween 20, pH 7.4) for 2 h at room temperature. 63 
Standard curves created with active human IgE (Abcam, Cambridge, UK) and undiluted 64 
serum samples were incubated for 2 h. Detection was performed with rabbit anti-human IgE 65 
antibody (1h, 1:2000; MIAB, Uppsala, Sweden) followed by alkaline phosphatase (AP) 66 
conjugated goat anti-rabbit antibody (1h, 1:1000; Jackson ImmunoResearch Laboratories, 67 
West Grove, PA). Finally, p-nitrophenyl phosphate substrate (Sigma, St. Louis, MO) was 68 
added and incubated for 15 min. The absorbance was measured at 405 nm. Sera with an IgE 69 
antibody level >100 kUA/l were re-run at 1:10 dilution. The IgE ELISAs were repeated with 70 
an inter-assay variation of 12%. IgE values to rFel d 7 were considered positive when the IgE 71 
level exceeded the mean of the 45 negative controls + 3 SD (kUA/l ≥0.12 to Fel d 7). IgE 72 
values to rCan f 1 were regarded as positive when the IgE level exceeded the previously 73 
established cut-off for rCan f 1 (≥0.1 kUA/l) (3).
 Spearman’s correlation test was used for 74 
comparing rFel d 7- and rCan f 1-specific IgE levels, where p<0.05 was considered 75 
significant. Analyses were performed using Graphpad Prism 5 software (Graphpad Software 76 
Inc., San Diego, CA).  77 
 78 
 79 
Basophil activation test  80 
Allergen-specific basophil degranulation was analyzed by monitoring the basophil activation 81 
markers CD203c and CD63, as previously described (4). Briefly, 10-fold serial dilutions of 82 
rFel d 7, rCan f 1 (10 μg/ml to 10-7 μg/ml) or two irrelevant control allergens (BSA from New 83 
England BioLabs, MA and rLep d 2.01, in house production), medium (negative control) and 84 
1 µg/ml rabbit anti-human IgE (Phadia AB, Uppsala, Sweden) were added to heparinized 85 
venous blood samples from four patients with doctor’s diagnosed allergy to cat and IgE 86 
positive to Fel d 7, whereof two were also co-sensitized to Can f 1. Serum from a non-atopic 87 
subject IgE negative to rFel d 7 (and Can f 1) was included as control. The samples were 88 
further incubated with FITC conjugated anti-CD63 and PE conjugated anti-CD203c 89 
monoclonal antibodies (clones CLBGran/12 and 97A6, respectively, Immunotech, Marseille, 90 
France) and analyzed by flow cytometry using a BD FACSCanto II (BD Biosciences, San 91 
Jose, CA). Data were analyzed using FlowJo (Treestar, Ashland, OR). Basophils were 92 
identified by gating for CD203c positive cells and the magnitude of allergen-activation was 93 
calculated and expressed as the percentage of CD63 positive cells among the gated basophils.  94 
Measurement of IgE cross-reactivity between Fel d 7 and Can f 1 95 
The potential cross-reactivity between IgE to Fel d 7 and Can f 1 was investigated by 96 
inhibition ELISA. The sera were diluted to 1 kUA/l and incubated at 1:1 v/v with 10-fold 97 
dilutions (range 10
1–10-7 µg/ml) of rFel d 7, rCan f 1 or PBS for 2 h at room temperature (5). 98 
Inhibition of IgE binding was analyzed by ELISA and calculated as [(ODno inhibitor – 99 
ODinhibitor)/OD no inhibitor] x100. Additionally, inhibition ELISA was performed using sera from 100 
two patients with IgE reactivity to rCan f 1 but not to rFel d 7. 101 
 102 
 103 
Synthesis and characterization of Can f 1 derived peptides and immunization of rabbits 104 
Six overlapping peptides spanning the Can f 1 sequence with a length between 30 and 36 105 
amino acids were designed based on the prediction of surface exposure of amino acids as 106 
determined by the ProtScale bioinformatics tool from the ExPASY server
 
(6) and were 107 
synthesized using an Applied Biosystems peptide synthesizer Model 433A (Foster City, CA). 108 
The peptides contained cysteins for coupling to keyhole limpet hemocyanin (KLH) either at N 109 
termini (Peptide 3, Peptide 4, Peptide 5 and Peptide 6) or at C termini (Peptide 1 and Peptide 110 
2) (Table S1). One Peptide, P4, contains a highly hydrophobic region of Can f 1 and was 111 
not used in further studies due to non-solubility in water or biological buffers. All the other 112 
peptides were purified by preparative HPLC (Dionex, Thermofischer Scientific, Waltham, 113 
MA) and their identities were confirmed by mass spectrometry (Bruker, Bremen, Germany). 114 
Can f 1 peptides were coupled to KLH (Pierce, ThermoFisher Scientific, Waltham, MA) and 115 
purified using a conjugation kit according to manufacturer`s instructions. The concentration 116 
of KLH-conjugated Can f 1 peptides was measured using the Micro BCA Assay Kit (Pierce, 117 
Rockford, IL). 118 
Peptide-specific IgG antibodies were obtained by immunizing rabbits three times (first 119 
booster injection after 4 weeks and a second booster injection after 7 weeks) with each of the 120 
KLH-conjugated peptides (200 µg/injection) and, for control purposes, with recombinant Can 121 
f 1 (200 µg/injection) using once Freund’s complete and twice Freund’s incomplete adjuvant 122 
(Charles River, Chatillon sur Chalaronnne, France). The “Directive 2010/63/EU of the 123 
European parliament and of the council (22 September 2010) on the protection of animals 124 
used for scientific purposes” were followed for the care and use of the animals. Five rabbit 125 
anti-Can f 1 peptide sera (diluted from 1:2000 to 1:50000) were used to evaluate cross-126 
reactive binding sites between Can f 1 and Fel d 7. IgG binding was analyzed by ELISA using 127 
rFel d 7, rCan f 1 and rFel d 1  coated plates incubated with rabbit anti-Can f 1 peptide 128 
antisera. Detection was performed with alkaline phosphatase conjugated goat-anti-rabbit IgG 129 
antibodies (1:1000, Jackson ImmunoResearch Laboratories, West Grove, PA). Detection was 130 
carried on like in IgE ELISA. 131 
 132 
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Table S1. Characteristic of synthetic Can f 1-derived peptides. 154 
No. Position (AA)* Sequence** # AA Molecular mass (Da) pI 
Peptide 1 1-35 CQDTPALGKDTVAVSGKWYLKAMTADQEVPEKPDSV 36 3879.37 4.53 
Peptide 2 31-60 CKPDSVTPMILKAQKGGNLEAKITMLTNGQ 30 3187.78 9.11 
Peptide 3 56-85 TNGQCQNITVVLHKTSEPGKYTAYEGQRVVC 31 3424.85 7.74 
Peptide 4 78-107 CAYEGQRVVFIQPSPVRDHYILYCEGELHGR 31 3636.12 6.03 
Peptide 5 101-132 CEGELHGRQIRMAKLLGRDPEQSQEALEDFWF 33 3919.36 4.59 
Peptide 6 127-156 EDFWEFSRAKGLNQEILELAQSETCSPGGQC 31 3473.79 4.14 
 155 
*, Position of amino acid without signal peptide; 156 
**, Bold and underlined sequences represent identical portions with Fel d 7; 157 
C, Addition of cysteine. 158 
 159 
160 
Table S2. Serological characteristics of the 65 rFel d 7-positive patients. 161 
Patient ID 
Cat 
   (kUA/l)
*
 
Dog 
(kUA/l)
*
 
rFel d 7 
(kUA/l)
**
 
rCan f 1 
(kUA/l)
**
 
1
 
 2.2 19 2.3 7.9 
2 3.4 14 7.2 13 
3 44 2.9 4.6 2.5 
4 14 16 37 33 
5 4.5 21 18 20 
6 24 12 11 8.3 
7 19 27 7.4 15 
8 110 29 11 18 
9 2.6 0.26 2.5 0.64 
10 190 58 14 29 
11 5.2 0.62 2.2 0.76 
12 60 7.2 28 9.9 
13 50 7 3.5 1.5 
14 17 12 9.1 11 
15 24 10 2.8 4.0 
16 6.6 2 2.6 2.4 
17 9.7 3.4 2.6 1.9 
18 2.5 7.4 2.0 1.9 
19 160 59 1.9 26 
20 44 36 1.6 31 
21 14 26 1.4 17 
22 16 11 1.3 2.2 
23 11 1.5 1.3 0.87 
24 6.1 0.87 1.2 0.38 
25 5.1 0.19 1.1 0.27 
26 14 1.1 1.1 1.4 
27 16 0.86 1.0 <0.10 
28 30 18 0.97 5.9 
29 34 3.7 0.70 <0.10 
30 19 8.9 0.62 1.2 
31 3.2 0.12 0.53 0.43 
32 9.4 16 0.44 29 
33 7.2 0.97 0.43 0.17 
34 14 36 0.35 0.89 
35 3.8 0.69 0.16 <0.10 
36 3 7.3 0.24 <0.10 
37 2.7 25 0.16 19 
38 9.6 10 0.93 4.2 
39 29 11 28 26 
40 165 11 27 4.8 
41 82 13 28 26 
42 6.0 41 2.8 1.4 
43 189 17 0.26 <0.10 
44 12 12 7.5 9.5 
45 111 24 28 29 
46 120 25 28 28 
47 67 54 25 25 
48 3.5 48 2.8 29 
49 12 56 1.4 29 
50 6.9 63 3.3 9.6 
51 13 66 27 26 
52 13 95 5.6 12 
53 68 80 26 28 
54 11 78 25 27 
55 105 60 29 28 
56 42 14 15 5.8 
57 11 51 0.9 0.67 
58 22 1.7 1.7 0.70 
59 6.2 7.9 17 16 
60 36 9.0 1.5 3.5 
61 69 18 32 32 
62 91 22 0.45 0.50 
63 88 28 30.5 7.4 
64 13 38 13 14 
65 4.0 22 9.5 25 
 162 
 
*, Specific IgE levels in kUA/l to cat and dog dander (ImmunoCAP; e1 and e5, respectively); 163 
 **,
 
 Allergen-specific IgE levels in kUA/l (ELISA). 164 
 
 165 
 166 
  167 
Table S3. Serological characteristics of patients in basophil activation test. 168 
Patient 
Cat 
   (kUA/l)
*
 
Dog 
(kUA/l)
*
 
rFel d 7 
(kUA/l)
**
 
rCan f 1 
(kUA/l)
**
 
I 1.6 0.31 0.46 0.1 
II 8.9 4.0 3.4 3.9 
III 10 1.8 5.1 <0.10 
IV 12 0.91 1.5 <0.10 
 169 
*, Specific IgE levels in kUA/l to cat and dog dander (ImmunoCAP; e1 and e5, respectively); 170 
 **,
 
Allergen-specific IgE levels in kUA/l (ELISA). 171 
  172 
    
 173 
 174 
Table S4. Percentages of secondary structure calculated in CDPro with CONTINILL 175 
algorithm using SP37 base. 176 
 177 
 178 
Secondary 
structure 
rFel d 7 
(%) 
rCan f 1 (%) Δ sum of α and β (%) 
α- helix 5.0 10.7  
β- sheets 36.0 40.9 14.2 
β-turn 24.2 27.8  
unfolded 34.8 20.6  
  179 
 180 
Figure S1 - IgE cross-reactivity between rFel d 7 and rCan f 1 in eight additional patients. 181 
Percentages of inhibition (y-axes) are plotted against different concentrations of inhibitor 182 
allergens (x-axes) in eight additional patients (5, 7, 10, 12, 15, 16, 19 and 20 in Table S2). 183 
IgE-binding to rCan f 1 in sera pre-incubated with rFel d 7–cross-inhibition (grey dots); IgE-184 
binding to rFel d 7 in sera pre-incubated with rCan f 1–cross-inhibition (black squares). 185 
 186 
 187 
 188 
Figure S2 - Structural similarities between Fel d 7 and Can f 1. (A) Sequence alignment of 189 
Fel d 7, Can f 1 and human tear lipocalin (hTL). Underlined sequences show the signal 190 
peptide and symbols underneath the alignment indicate: positions which have a single, fully 191 
conserved residue (*), conservation between groups of strongly similar properties (:) and 192 
weakly similar properties (.). Percentages of sequence identity between: Fel d 7 vs Can f 1 193 
63%, Fel d 7 and hTL  55%, Can f 1 and hTL  60%.; (B) Far UV CD spectra of rFel d 7 (solid 194 
line) and rCan f 1 (dashed line); (C) Near UV CD spectra of rFel d 7 (solid line) and rCan f 1 195 
(dashed line). 196 
 197 
 198 
Figure S3 - Can f 1 peptide-specific IgG binding. (A) to rFel d 7; (B) to rCan f 1; (C) to the 199 
unrelated allergen rFel d 1.Optical density values corresponding to allergen-specific IgG 200 
levels (y-axis) of different dilutions of peptide-specific antisera (x-axis). 201 
